Physician profile
Mack C Mitchell
NPI 1710938279
$20,026.00
in general payments reported to CMS, 2019-2025
11 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,250 · 2020: $5,000 · 2023: $741 · 2024: $12K · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $716 · Travel and Lodging: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,600.00 |
| Food and Beverage | $716.32 |
| Travel and Lodging | $459.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,304.70 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $5,000.00 | 2020 | |
| Amag Pharmaceuticals, INC. | $2,250.00 | 2019 | |
| Novo Nordisk INC | $152.45 | 2025 | Wegovy |
| Ardelyx, INC. | $79.83 | 2025 | Ibsrela |
| Abbvie INC. | $68.14 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.60 | 2023-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $47.58 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $27.83 | 2025 | Rezdiffra |
| Pfizer INC. | $22.05 | 2025 | |
| Celltrion USA INC. | $16.82 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mack Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.